[
  {
    "ts": null,
    "headline": "Pfizer (PFE) Dips More Than Broader Market: What You Should Know",
    "summary": "In the most recent trading session, Pfizer (PFE) closed at $23.27, indicating a -2.29% shift from the previous trading day.",
    "url": "https://finnhub.io/api/news?id=a9c9f6fd6ea15eefaa26677079346e443f1aef14da901d3ec87cab5ad7bfe8cc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753998303,
      "headline": "Pfizer (PFE) Dips More Than Broader Market: What You Should Know",
      "id": 136161099,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "In the most recent trading session, Pfizer (PFE) closed at $23.27, indicating a -2.29% shift from the previous trading day.",
      "url": "https://finnhub.io/api/news?id=a9c9f6fd6ea15eefaa26677079346e443f1aef14da901d3ec87cab5ad7bfe8cc"
    }
  },
  {
    "ts": null,
    "headline": "Trump Talks Tough on Drug Prices but His Demands Have Softened",
    "summary": "The president threatened to “deploy every tool” in the administration’s arsenal if drug companies don’t cut certain prices by late September.",
    "url": "https://finnhub.io/api/news?id=abfd0cbc3bdf5cf7eec493e57c4c23222429aa6d3fbd91ae1cf65b8720b77b7a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753997100,
      "headline": "Trump Talks Tough on Drug Prices but His Demands Have Softened",
      "id": 136160929,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The president threatened to “deploy every tool” in the administration’s arsenal if drug companies don’t cut certain prices by late September.",
      "url": "https://finnhub.io/api/news?id=abfd0cbc3bdf5cf7eec493e57c4c23222429aa6d3fbd91ae1cf65b8720b77b7a"
    }
  },
  {
    "ts": null,
    "headline": "What Trump's Big Pharma CEO letters mean for drug pricing power",
    "summary": "President Trump is turning up the heat on Big Pharma, sending letters to 17 major drugmakers demanding lower prices across their entire portfolios. Yahoo Finance Senior Reporter Anjalee Khemlani joins Market Domination to explain how the administration is pushing for most-favored-nation pricing and giving companies until September 29 to comply. To watch more expert insights and analysis on the latest market action, check out more Market Domination.",
    "url": "https://finnhub.io/api/news?id=4833e7f299553f7689706923f0de2bea0e4ca660804c1eee2c139edccb399c18",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753992991,
      "headline": "What Trump's Big Pharma CEO letters mean for drug pricing power",
      "id": 136160870,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "President Trump is turning up the heat on Big Pharma, sending letters to 17 major drugmakers demanding lower prices across their entire portfolios. Yahoo Finance Senior Reporter Anjalee Khemlani joins Market Domination to explain how the administration is pushing for most-favored-nation pricing and giving companies until September 29 to comply. To watch more expert insights and analysis on the latest market action, check out more Market Domination.",
      "url": "https://finnhub.io/api/news?id=4833e7f299553f7689706923f0de2bea0e4ca660804c1eee2c139edccb399c18"
    }
  },
  {
    "ts": null,
    "headline": "Trump sends letters to pharma CEOs demanding they reduce drug prices in 60 days",
    "summary": "President Trump sent letters to 17 CEOs of drug companies to force them to reduce prices within 60 days.",
    "url": "https://finnhub.io/api/news?id=a4d1603df39e6d5c3d6208cb4aa5419cb3cf80daa0a6805899a1ecb7c4dee65f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753990810,
      "headline": "Trump sends letters to pharma CEOs demanding they reduce drug prices in 60 days",
      "id": 136160872,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "President Trump sent letters to 17 CEOs of drug companies to force them to reduce prices within 60 days.",
      "url": "https://finnhub.io/api/news?id=a4d1603df39e6d5c3d6208cb4aa5419cb3cf80daa0a6805899a1ecb7c4dee65f"
    }
  },
  {
    "ts": null,
    "headline": "Trump Sends Letters to 17 Pharmaceutical Companies Asking Them to Lower Costs",
    "summary": "President Trump sent letters to 17 pharmaceutical companies on Thursday asking them to lower costs of drugs for U.S. consumers to the lowest price offered in other developed nations, following up on an executive order issued in May.",
    "url": "https://finnhub.io/api/news?id=6c9fe155402ddc330d8fc8a3f0a9c10084ffc5e5c1b09cdba3c34ed81efc1a64",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753986626,
      "headline": "Trump Sends Letters to 17 Pharmaceutical Companies Asking Them to Lower Costs",
      "id": 136160873,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "President Trump sent letters to 17 pharmaceutical companies on Thursday asking them to lower costs of drugs for U.S. consumers to the lowest price offered in other developed nations, following up on an executive order issued in May.",
      "url": "https://finnhub.io/api/news?id=6c9fe155402ddc330d8fc8a3f0a9c10084ffc5e5c1b09cdba3c34ed81efc1a64"
    }
  },
  {
    "ts": null,
    "headline": "Trump demands largest pharma companies slash US drug prices",
    "summary": "(Bloomberg) -- President Donald Trump sent letters to 17 of the world’s largest pharmaceutical companies — including Eli Lilly & Co., Novo Nordisk A/S and Pfizer Inc. — insisting they slash their US prices on new drugs to the lowest amount paid by certain other countries.Most Read from BloombergThe World’s Data Center Capital Has Residents SurroundedAn Abandoned Art-Deco Landmark in Buffalo Awaits RevivalWe Should All Be Biking Along the BeachBudapest’s Most Historic Site Gets a Controversial Re",
    "url": "https://finnhub.io/api/news?id=292aa5d0e8c41af62ddead7ad247376e84410f5a02b83d2a1a0bbf469f796efb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753985112,
      "headline": "Trump demands largest pharma companies slash US drug prices",
      "id": 136160875,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "(Bloomberg) -- President Donald Trump sent letters to 17 of the world’s largest pharmaceutical companies — including Eli Lilly & Co., Novo Nordisk A/S and Pfizer Inc. — insisting they slash their US prices on new drugs to the lowest amount paid by certain other countries.Most Read from BloombergThe World’s Data Center Capital Has Residents SurroundedAn Abandoned Art-Deco Landmark in Buffalo Awaits RevivalWe Should All Be Biking Along the BeachBudapest’s Most Historic Site Gets a Controversial Re",
      "url": "https://finnhub.io/api/news?id=292aa5d0e8c41af62ddead7ad247376e84410f5a02b83d2a1a0bbf469f796efb"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Inc. stock underperforms Thursday when compared to competitors",
    "summary": "Pfizer Inc. stock underperforms Thursday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=1c21445c3896aad0e83f594de57012ff22a1f5a7a8158669c12bd292d8284d0e",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753979820,
      "headline": "Pfizer Inc. stock underperforms Thursday when compared to competitors",
      "id": 136169775,
      "image": "",
      "related": "PFE",
      "source": "MarketWatch",
      "summary": "Pfizer Inc. stock underperforms Thursday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=1c21445c3896aad0e83f594de57012ff22a1f5a7a8158669c12bd292d8284d0e"
    }
  },
  {
    "ts": null,
    "headline": "Microsoft Q4 Earnings & Revenues Beat on Cloud Business Expansion",
    "summary": "MSFT's fourth-quarter fiscal 2025 results reflect strength in the AI business and Copilot adoption, backed by accelerating growth in its Azure cloud infrastructure unit.",
    "url": "https://finnhub.io/api/news?id=9ffb11d2cf213670c1157f1e6bbd3d091d209b9fcc8f81b5efd34bc71170924c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753978080,
      "headline": "Microsoft Q4 Earnings & Revenues Beat on Cloud Business Expansion",
      "id": 136161105,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "MSFT's fourth-quarter fiscal 2025 results reflect strength in the AI business and Copilot adoption, backed by accelerating growth in its Azure cloud infrastructure unit.",
      "url": "https://finnhub.io/api/news?id=9ffb11d2cf213670c1157f1e6bbd3d091d209b9fcc8f81b5efd34bc71170924c"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Beats on Q2 Earnings and Sales, Raises '25 Sales View",
    "summary": "BMY's Q2 EPS and revenues beat estimates, powered by strong Growth portfolio sales and a lesser than expected decline in Legacy portfolio sales.",
    "url": "https://finnhub.io/api/news?id=7923eb4896a0b4806efeb21e3af205575e32016179da94ee7feaa6797471ad63",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753976580,
      "headline": "Bristol Myers Beats on Q2 Earnings and Sales, Raises '25 Sales View",
      "id": 136155302,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "BMY's Q2 EPS and revenues beat estimates, powered by strong Growth portfolio sales and a lesser than expected decline in Legacy portfolio sales.",
      "url": "https://finnhub.io/api/news?id=7923eb4896a0b4806efeb21e3af205575e32016179da94ee7feaa6797471ad63"
    }
  },
  {
    "ts": null,
    "headline": "Vaxcyte, Inc. (PCVX)’s VAX-24 Achieves Phase 2 Success in Infants",
    "summary": "We recently compiled a list of 11 Best Future Stocks to Buy Now. Vaxcyte, Inc. stands second on our list among the best future stocks. Vaxcyte, Inc. (NASDAQ:PCVX) is a clinical-stage biotech company focused on developing next-generation pneumococcal conjugate vaccines (PCVs) to prevent invasive pneumococcal disease (IPD). The company recently reported positive topline results from […]",
    "url": "https://finnhub.io/api/news?id=f26713d8e2123e35345405263abd4f000fe075d5941646eb209026ef7ed0c61e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753976133,
      "headline": "Vaxcyte, Inc. (PCVX)’s VAX-24 Achieves Phase 2 Success in Infants",
      "id": 136155229,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "We recently compiled a list of 11 Best Future Stocks to Buy Now. Vaxcyte, Inc. stands second on our list among the best future stocks. Vaxcyte, Inc. (NASDAQ:PCVX) is a clinical-stage biotech company focused on developing next-generation pneumococcal conjugate vaccines (PCVs) to prevent invasive pneumococcal disease (IPD). The company recently reported positive topline results from […]",
      "url": "https://finnhub.io/api/news?id=f26713d8e2123e35345405263abd4f000fe075d5941646eb209026ef7ed0c61e"
    }
  },
  {
    "ts": null,
    "headline": "Alnylam: Amvuttra Is Just Getting Started",
    "summary": "Alnylam Pharmaceuticals, Inc. shares soar with strong Q2 results, driven by Amvuttra's stellar U.S. launch for ATTR amyloidosis. Click for my ALNY earnings update.",
    "url": "https://finnhub.io/api/news?id=c822e6766b4b07b0a3df042ab4796d590c9bba72986b14a0abd493eccb8c6150",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753974800,
      "headline": "Alnylam: Amvuttra Is Just Getting Started",
      "id": 136157257,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2157258156/image_2157258156.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Alnylam Pharmaceuticals, Inc. shares soar with strong Q2 results, driven by Amvuttra's stellar U.S. launch for ATTR amyloidosis. Click for my ALNY earnings update.",
      "url": "https://finnhub.io/api/news?id=c822e6766b4b07b0a3df042ab4796d590c9bba72986b14a0abd493eccb8c6150"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly (LLY) Reports Next Week: Wall Street Expects Earnings Growth",
    "summary": "Lilly (LLY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
    "url": "https://finnhub.io/api/news?id=44247ebe19dea9f5a0c21858a137dc32ed132fbc81d573c575182eef76c1c4a8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753970424,
      "headline": "Eli Lilly (LLY) Reports Next Week: Wall Street Expects Earnings Growth",
      "id": 136155098,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Lilly (LLY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
      "url": "https://finnhub.io/api/news?id=44247ebe19dea9f5a0c21858a137dc32ed132fbc81d573c575182eef76c1c4a8"
    }
  },
  {
    "ts": null,
    "headline": "The three-year shareholder returns and company earnings persist lower as Pfizer (NYSE:PFE) stock falls a further 6.1% in past week",
    "summary": "For many investors, the main point of stock picking is to generate higher returns than the overall market. But in any...",
    "url": "https://finnhub.io/api/news?id=1d17fd687ffcc5b729e0a45a912d36bef9a0cbc6981cd0367df326d01d4cae31",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753970416,
      "headline": "The three-year shareholder returns and company earnings persist lower as Pfizer (NYSE:PFE) stock falls a further 6.1% in past week",
      "id": 136155231,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "For many investors, the main point of stock picking is to generate higher returns than the overall market. But in any...",
      "url": "https://finnhub.io/api/news?id=1d17fd687ffcc5b729e0a45a912d36bef9a0cbc6981cd0367df326d01d4cae31"
    }
  },
  {
    "ts": null,
    "headline": "Should You Buy Pfizer (PFE) Stock Before August 5? Here's What History Says",
    "summary": "Pfizer presents a good buying opportunity, but not because of potential earnings.",
    "url": "https://finnhub.io/api/news?id=563f2a019100625586a3a3999b80895f943e533b37f3bfb72c684750f4515987",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753969980,
      "headline": "Should You Buy Pfizer (PFE) Stock Before August 5? Here's What History Says",
      "id": 136155232,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer presents a good buying opportunity, but not because of potential earnings.",
      "url": "https://finnhub.io/api/news?id=563f2a019100625586a3a3999b80895f943e533b37f3bfb72c684750f4515987"
    }
  },
  {
    "ts": null,
    "headline": "Stay Ahead of the Game With Pfizer (PFE) Q2 Earnings: Wall Street's Insights on Key Metrics",
    "summary": "Besides Wall Street's top-and-bottom-line estimates for Pfizer (PFE), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2025.",
    "url": "https://finnhub.io/api/news?id=9254fdc37a3234795254a9dd87057bf6813b27c4c1dd49a2265091f6825f44f1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753967705,
      "headline": "Stay Ahead of the Game With Pfizer (PFE) Q2 Earnings: Wall Street's Insights on Key Metrics",
      "id": 136155233,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Besides Wall Street's top-and-bottom-line estimates for Pfizer (PFE), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2025.",
      "url": "https://finnhub.io/api/news?id=9254fdc37a3234795254a9dd87057bf6813b27c4c1dd49a2265091f6825f44f1"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie (ABBV) Tops Q2 Earnings and Revenue Estimates",
    "summary": "AbbVie (ABBV) delivered earnings and revenue surprises of +2.77% and +2.35%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?",
    "url": "https://finnhub.io/api/news?id=282f8887f0427f7d5c12e37b325e294493cc24023f8a79c228b7f83e56b1bb57",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753966501,
      "headline": "AbbVie (ABBV) Tops Q2 Earnings and Revenue Estimates",
      "id": 136155124,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "AbbVie (ABBV) delivered earnings and revenue surprises of +2.77% and +2.35%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?",
      "url": "https://finnhub.io/api/news?id=282f8887f0427f7d5c12e37b325e294493cc24023f8a79c228b7f83e56b1bb57"
    }
  },
  {
    "ts": null,
    "headline": "Marengo Therapeutics Bolsters Advisory Strength with Appointment of Dr. Mikael Dolsten to its Board of Directors and Dr. Josep Tabernero to its Scientific Advisory Board",
    "summary": "Marengo Therapeutics, Inc., a clinical-stage biotechnology company pioneering novel approaches for precision immunotherapy in oncology, inflammation and immunology (I&I), today announced the appointment of Mikael Dolsten, M.D., Ph.D., as an independent member of its Board of Directors, and Josep Tabernero, M.D., Ph.D., to its Scientific Advisory Board (SAB).",
    "url": "https://finnhub.io/api/news?id=44b5f36518a919df419d0e7cd11594b950aa6a22ac9287a9588192e145118267",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753959600,
      "headline": "Marengo Therapeutics Bolsters Advisory Strength with Appointment of Dr. Mikael Dolsten to its Board of Directors and Dr. Josep Tabernero to its Scientific Advisory Board",
      "id": 136151907,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Marengo Therapeutics, Inc., a clinical-stage biotechnology company pioneering novel approaches for precision immunotherapy in oncology, inflammation and immunology (I&I), today announced the appointment of Mikael Dolsten, M.D., Ph.D., as an independent member of its Board of Directors, and Josep Tabernero, M.D., Ph.D., to its Scientific Advisory Board (SAB).",
      "url": "https://finnhub.io/api/news?id=44b5f36518a919df419d0e7cd11594b950aa6a22ac9287a9588192e145118267"
    }
  },
  {
    "ts": null,
    "headline": "Renal Failure Clinical Trials Market Landscape Report 2025 Featuring Bayer, AstraZeneca, Amgen, Sanofi, Novartis, AbbVie, Roche, Pfizer, Takeda, Astellas",
    "summary": "Discover key insights with the \"Renal Failure - Global Clinical Trials Review, 2025.\" This comprehensive report offers an overview of Renal Failure clinical trials, covering trial numbers, phases, statuses, and sponsor types globally. Stay ahead with data-driven decisions and gain competitive advantage.Dublin, July 31, 2025 (GLOBE NEWSWIRE) -- The \"Renal Failure - Global Clinical Trials Review, 2025\" clinical trials has been added to ResearchAndMarkets.com's offering.The clinical trial report pr",
    "url": "https://finnhub.io/api/news?id=7387ca0de66b5f22e1f2c30bda60d37e485fcf2d727def98fb5269bb66488e21",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753955100,
      "headline": "Renal Failure Clinical Trials Market Landscape Report 2025 Featuring Bayer, AstraZeneca, Amgen, Sanofi, Novartis, AbbVie, Roche, Pfizer, Takeda, Astellas",
      "id": 136151802,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Discover key insights with the \"Renal Failure - Global Clinical Trials Review, 2025.\" This comprehensive report offers an overview of Renal Failure clinical trials, covering trial numbers, phases, statuses, and sponsor types globally. Stay ahead with data-driven decisions and gain competitive advantage.Dublin, July 31, 2025 (GLOBE NEWSWIRE) -- The \"Renal Failure - Global Clinical Trials Review, 2025\" clinical trials has been added to ResearchAndMarkets.com's offering.The clinical trial report pr",
      "url": "https://finnhub.io/api/news?id=7387ca0de66b5f22e1f2c30bda60d37e485fcf2d727def98fb5269bb66488e21"
    }
  },
  {
    "ts": null,
    "headline": "Systemic Lupus Erythematosus Clinical Trials Market Landscape Report 2025 Featuring GSK, BMS, AstraZeneca, Thermo Fisher Scientific, ICON, IQVIA, Parexel, Laboratory Corp of America, Novartis, Pfizer",
    "summary": "Discover comprehensive insights into the global Systemic Lupus Erythematosus clinical trials landscape with the \"Systemic Lupus Erythematosus - Global Clinical Trials Review, 2025\". The report offers detailed analyses of trial data by region, country, phase, status, and sponsor type, assisting in strategic planning and competitive positioning.Dublin, July 31, 2025 (GLOBE NEWSWIRE) -- The \"Systemic Lupus Erythematosus - Global Clinical Trials Review, 2025\" clinical trials has been added to Resear",
    "url": "https://finnhub.io/api/news?id=b0e0f30693fd3b663d2b5982a35af25378749958f1e7be6a19ab6c57d8ac33f5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753954860,
      "headline": "Systemic Lupus Erythematosus Clinical Trials Market Landscape Report 2025 Featuring GSK, BMS, AstraZeneca, Thermo Fisher Scientific, ICON, IQVIA, Parexel, Laboratory Corp of America, Novartis, Pfizer",
      "id": 136151865,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Discover comprehensive insights into the global Systemic Lupus Erythematosus clinical trials landscape with the \"Systemic Lupus Erythematosus - Global Clinical Trials Review, 2025\". The report offers detailed analyses of trial data by region, country, phase, status, and sponsor type, assisting in strategic planning and competitive positioning.Dublin, July 31, 2025 (GLOBE NEWSWIRE) -- The \"Systemic Lupus Erythematosus - Global Clinical Trials Review, 2025\" clinical trials has been added to Resear",
      "url": "https://finnhub.io/api/news?id=b0e0f30693fd3b663d2b5982a35af25378749958f1e7be6a19ab6c57d8ac33f5"
    }
  },
  {
    "ts": null,
    "headline": "Mycosis Fungoides Clinical Trials Market Landscape Report 2025 Featuring Pfizer, Bristol-Myers Squibb, Kirin, Takeda, Johnson & Johnson, Merck, Soligenix, Eisai, Novartis, ICON",
    "summary": "Discover key insights in the \"Mycosis Fungoides - Global Clinical Trials Review, 2025.\" This comprehensive report covers global trial scenarios, detailing enrollment trends, regional data (G7 & E7), and prominent drugs. Leverage informed decision-making and strategic planning with the latest trial landscape analysis.Dublin, July 31, 2025 (GLOBE NEWSWIRE) -- The \"Mycosis Fungoides - Global Clinical Trials Review, 2025\" clinical trials has been added to ResearchAndMarkets.com's offering.The clinic",
    "url": "https://finnhub.io/api/news?id=b1005680d0fa7c1ba1ae6f6256db21ea0421ec327bdb7a819910038b212a4c02",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753954260,
      "headline": "Mycosis Fungoides Clinical Trials Market Landscape Report 2025 Featuring Pfizer, Bristol-Myers Squibb, Kirin, Takeda, Johnson & Johnson, Merck, Soligenix, Eisai, Novartis, ICON",
      "id": 136151783,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Discover key insights in the \"Mycosis Fungoides - Global Clinical Trials Review, 2025.\" This comprehensive report covers global trial scenarios, detailing enrollment trends, regional data (G7 & E7), and prominent drugs. Leverage informed decision-making and strategic planning with the latest trial landscape analysis.Dublin, July 31, 2025 (GLOBE NEWSWIRE) -- The \"Mycosis Fungoides - Global Clinical Trials Review, 2025\" clinical trials has been added to ResearchAndMarkets.com's offering.The clinic",
      "url": "https://finnhub.io/api/news?id=b1005680d0fa7c1ba1ae6f6256db21ea0421ec327bdb7a819910038b212a4c02"
    }
  },
  {
    "ts": null,
    "headline": "Glaucoma Global Clinical Trials Market Landscape Report 2025 Featuring Alcon, AbbVie, Santen Pharmaceutical, Pfizer, Kowa, Viatris, Merck, Novartis, Senju Pharmaceutical, Bausch Health",
    "summary": "Discover insights with the \"Glaucoma - Global Clinical Trials Review, 2025.\" This comprehensive report outlines the global scenario of glaucoma clinical trials, offering top-line data by region, country, phase, and sponsor type. Leverage key findings to enhance decision-making and optimize strategies in the competitive clinical trials landscape.Dublin, July 31, 2025 (GLOBE NEWSWIRE) -- The \"Glaucoma - Global Clinical Trials Review, 2025\" has been added to ResearchAndMarkets.com's offering. The c",
    "url": "https://finnhub.io/api/news?id=c693a38a686efe72f5da5591f613698427afe75985b2c1bc3721fa2d3897d600",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753954020,
      "headline": "Glaucoma Global Clinical Trials Market Landscape Report 2025 Featuring Alcon, AbbVie, Santen Pharmaceutical, Pfizer, Kowa, Viatris, Merck, Novartis, Senju Pharmaceutical, Bausch Health",
      "id": 136151804,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Discover insights with the \"Glaucoma - Global Clinical Trials Review, 2025.\" This comprehensive report outlines the global scenario of glaucoma clinical trials, offering top-line data by region, country, phase, and sponsor type. Leverage key findings to enhance decision-making and optimize strategies in the competitive clinical trials landscape.Dublin, July 31, 2025 (GLOBE NEWSWIRE) -- The \"Glaucoma - Global Clinical Trials Review, 2025\" has been added to ResearchAndMarkets.com's offering. The c",
      "url": "https://finnhub.io/api/news?id=c693a38a686efe72f5da5591f613698427afe75985b2c1bc3721fa2d3897d600"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer: Lack Of Enthusiasm Shouldn't Surprise You",
    "summary": "Pfizer faces weak growth, sector headwinds, and pipeline uncertainty despite cost cuts and a 7% yield, weighing on sentiment. Find out why PFE stock is a hold.",
    "url": "https://finnhub.io/api/news?id=9d0c5685537138e39237b360770c934273409af0a6c0dd2a4fcff6fab08e9810",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753952400,
      "headline": "Pfizer: Lack Of Enthusiasm Shouldn't Surprise You",
      "id": 136151500,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1292440985/image_1292440985.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Pfizer faces weak growth, sector headwinds, and pipeline uncertainty despite cost cuts and a 7% yield, weighing on sentiment. Find out why PFE stock is a hold.",
      "url": "https://finnhub.io/api/news?id=9d0c5685537138e39237b360770c934273409af0a6c0dd2a4fcff6fab08e9810"
    }
  },
  {
    "ts": null,
    "headline": "Where Will Pfizer (PFE) Be in 5 Years?",
    "summary": "The big drugmaker should be even bigger over the next five years despite facing a patent cliff.",
    "url": "https://finnhub.io/api/news?id=74f38b327995da769eb4fc4e8c5cbf41087585acf68bea5c2ebc63ba6710c20f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753951860,
      "headline": "Where Will Pfizer (PFE) Be in 5 Years?",
      "id": 136151912,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The big drugmaker should be even bigger over the next five years despite facing a patent cliff.",
      "url": "https://finnhub.io/api/news?id=74f38b327995da769eb4fc4e8c5cbf41087585acf68bea5c2ebc63ba6710c20f"
    }
  },
  {
    "ts": null,
    "headline": "Ireland awakens to the risk of relying on US investment",
    "summary": "At first glance, Ringaskiddy looks like any other quiet village on Ireland’s south coast. But it has one claim to fame: the sprawling Pfizer...",
    "url": "https://finnhub.io/api/news?id=fd895330cb1e32b792041bc7fc307b788f1f8a7aa388c1c8759e685a8d36de9e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753934404,
      "headline": "Ireland awakens to the risk of relying on US investment",
      "id": 136148646,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "At first glance, Ringaskiddy looks like any other quiet village on Ireland’s south coast. But it has one claim to fame: the sprawling Pfizer...",
      "url": "https://finnhub.io/api/news?id=fd895330cb1e32b792041bc7fc307b788f1f8a7aa388c1c8759e685a8d36de9e"
    }
  },
  {
    "ts": null,
    "headline": "Bank of America Securities Maintains a Hold on Pfizer (PFE)",
    "summary": "Pfizer Inc. (NYSE:PFE) is one of the most undervalued blue chip stocks to buy according to hedge funds. Analyst Tim Anderson from Bank of America Securities maintained a Hold rating on Pfizer Inc. (NYSE:PFE) on July 25, setting a $27.00 price target. The analyst based the rating on Pfizer Inc.’s (NYSE:PFE) future outlook and current […]",
    "url": "https://finnhub.io/api/news?id=03c372dd42b098a17a1a75a62c3133204f0f9afe372bd102a6ab509b2457d1fa",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753934372,
      "headline": "Bank of America Securities Maintains a Hold on Pfizer (PFE)",
      "id": 136149085,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer Inc. (NYSE:PFE) is one of the most undervalued blue chip stocks to buy according to hedge funds. Analyst Tim Anderson from Bank of America Securities maintained a Hold rating on Pfizer Inc. (NYSE:PFE) on July 25, setting a $27.00 price target. The analyst based the rating on Pfizer Inc.’s (NYSE:PFE) future outlook and current […]",
      "url": "https://finnhub.io/api/news?id=03c372dd42b098a17a1a75a62c3133204f0f9afe372bd102a6ab509b2457d1fa"
    }
  }
]